Skip to main content
ARTELO BIOSCIENCES, INC. logo

ARTELO BIOSCIENCES, INC. — Investor Relations & Filings

Ticker · ARTL ISIN · US04301G7060 US Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2021-02-17 Director's Dealing
Country US United States of America
Listing US ARTL

About ARTELO BIOSCIENCES, INC.

https://artelobio.com/

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. The company's scientific approach is centered on modifying lipid-signaling pathways, particularly by modulating the endocannabinoid system. Its primary therapeutic focus is on developing improved treatments for patients with cancer and other serious diseases. Artelo is advancing a diverse portfolio of drug candidates through its development pipeline to address unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2021-02-17 English
FORM 4
Director's Dealing
2021-02-17 English
FORM 4
Director's Dealing
2021-02-17 English
FORM 4
Director's Dealing
2021-02-17 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The key content is about the grant of stock options to the CEO, which is a change in compensatory arrangements for a senior officer. This fits the category of Board/Management Information (MANG), as it announces management compensation changes and appointments. The document is short (3537 characters) and does not contain financial statements or detailed financial data, so it is not an Annual Report or Earnings Release. It is not a report publication announcement or a certification. Therefore, the best classification is MANG with high confidence.
2021-02-17 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically discusses a notification from Nasdaq confirming the company's compliance with the minimum bid price requirement, which is an update on listing status. The document is short (3137 characters) and does not contain financial statements or detailed financial analysis. It is not an annual or quarterly report, nor an earnings release or management discussion. It is an official regulatory filing reporting a specific event. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-02-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.